Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2169-2177

  Aravantinos, Gerasimos ^a   Fountzilas, George ^b   Bamias, Aristotelis ^c   Grimani, Irene ^d   Rizos, Spyridon ^a   Kalofonos, Haralabos P ^e   Skarlos, Dimosthenis V ^f   Economopoulos, Theofanis ^g   Kosmidis, Paris A ^h   Stathopoulos, George P ⁱ   Briasoulis, Evangelos ^j   Pectasides, Dimitrios ^g   Samantas, Epaminondas ^a   Timotheadou, Eleni ^b   Papadimitriou, Christos ^c   Papanikolaou, Alexandros ^b   Onyenadum, Adimchi ^e   Papakostas, Pavlos ^k   Bafaloukos, Dimitrios ^f   Dimopoulos, Meletios A ^c  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f Metropolitan Hospital   (Greece)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h HYGEIA HOSPITAL   (Greece)

ⁱ HENRY DUNANT HOSPITAL   (Greece)

^j UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^k HIPPOKRATION HOSPITAL   (Greece)

more..

Author keywords

Advanced; Anthracycline; Carboplatin; Chemotherapy; Cisplatin; Doxorubicin; First line; Initial; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; CREATININE; DEXAMETHASONE; DIMETINDENE; DOXORUBICIN; ELECTROLYTE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; PACLITAXEL; PROMETHAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; KIDNEY FUNCTION TEST; LABORATORY DIAGNOSIS; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 54849162900     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.035     Document Type: Article

References (27)

1. McGuire W.P., Hoskins W.J., Brady M.R., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Engl J Med 334 (1996) 1-6
2. McGuire W.P., and Ozols R.F. Chemotherapy of advanced ovarian cancer. Sem Oncol 25 (1998) 340-348
3. Piccart M.J., Bertelsen K., James K., et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer. J Natl Cancer Inst 92 (2000) 699-708
4. Bookman M.A., McGuire W.P., Kilpatrick D., et al. Carboplatin and Paclitaxel in ovarian carcinoma: a phase I study of the gynecologic oncology Group. J Clin Oncol 14 (1996) 1895-1902
5. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21 (2003) 3194-3200
6. du Bois A., Luck H.J., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 17 (2003) 1320-1329
7. Neijt J.P., Engelholm S.A., Tuxen M.K., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18 (2000) 3084-3092
8. Aravantinos G., Fountzilas G., Kosmidis P., et al. Paclitaxel plus Carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC) long-term efficacy results. Ann Oncol 16 7 (2005) 1116-1122
9. Vermorken JB, Bollis G, van Rijswijk RE, et al. High-dose intensity regimens with epirubicin in ovarian cancer.
10. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis - Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991; 9:1668-74.
11. Fanning J., Bennett T.Z., and Hilgers R.D. Metaanalysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80 (1992) 954-960
12. A' Hern R.P., and Gore M.E. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 3 (1995) 726-732
13. Hill M., Macfarlane V., Moore J., et al. Taxane, platinum, anthracycline combination therapy in advanced epithelial ovarian cancer. Sem Oncol 24 Suppl 2 (1997) 34-37
14. Naumann R.W., Alvarez R.D., Omura G.A., et al. A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer. Gynecol Oncol 71 (1998) 450-453
15. Calvert A.H., Newell R., Gumbrell L.A., et al. Carboplatin dosage prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
16. Jelliffe R.W. Creatinine clearance: Bedside estimate. Ann Intern Med 79 (1973) 604-605
17. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
18. du Bois A., Weber B., Rochon J., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24 7, Mar 1 (2006) 1127-1135
19. Kristensen G.B., Vergote I., Eisenhauer E., et al. First line Treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC): A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG,and NCIC CTG-Results on progression free survival. J Clin Oncol 23 Suppl. (2004) 449s abstr 5003
20. Vergote I., Gorp T.V., Cadron I., et al. Improving outcome in the first-line management of advanced ovarian cancer. Eur J Cancer Suppl.5, No 1 (2007) 23-28
21. Bookman, et al. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma (O). J.Clin Oncol 24 18s (2006) 256s abst 5002
22. Pignata S., Scambia G., Savarese A., et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO-2 randomized multicenter trial. J Clin Oncol 23 16s (2005) 458s [abst 5014]
23. Fruscio R, Colombo N, Lissoni AA,et al. A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.Br J Cancer. 2008 Feb 5 [Epub ahead of print].
24. Penson R.T., Cannistra S.A., Seiden M.V., et al. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J.Clin Oncol 24 18s (2006) 260s [abst 5020]
25. Aghajanian C., Sabbatini P., Derosa F., et al. A phase II study of cetuximab/paclitaxel/carboplatin for the Initial treatment of advanced stage ovarian, primary peritoneal, and Fallopian Tube Cancer. J Clin Oncol 23 16s (2005) 466s [abst 5047]
26. Blank S.V., Curtin J.P., Goldman N.A., et al. Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. J Clin Oncol 24 18s (2006) 274s [abst 5076]
27. Schroder W., Campone M., Abadie S., et al. A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). J Clin Oncol 24 18s (2006) 274s [abst 5075]